US20070027105A1 - Peroxide removal from drug delivery vehicle - Google Patents

Peroxide removal from drug delivery vehicle Download PDF

Info

Publication number
US20070027105A1
US20070027105A1 US11/492,153 US49215306A US2007027105A1 US 20070027105 A1 US20070027105 A1 US 20070027105A1 US 49215306 A US49215306 A US 49215306A US 2007027105 A1 US2007027105 A1 US 2007027105A1
Authority
US
United States
Prior art keywords
drug delivery
delivery vehicle
formulation
saib
peroxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/492,153
Other languages
English (en)
Inventor
Gunjan Junnarkar
Michael Desjardin
John Carr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Durect Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Priority to US11/492,153 priority Critical patent/US20070027105A1/en
Priority to KR1020087004459A priority patent/KR20080059149A/ko
Priority to EP15181255.9A priority patent/EP2977061B1/en
Priority to BRPI0614156-0A priority patent/BRPI0614156A2/pt
Priority to DK14178214.4T priority patent/DK2810658T3/en
Priority to ES15181255.9T priority patent/ES2632496T3/es
Priority to SI200631978T priority patent/SI2810658T1/sl
Priority to AU2006275987A priority patent/AU2006275987A1/en
Priority to HUE14178214A priority patent/HUE027925T2/en
Priority to EA200800415A priority patent/EA200800415A1/ru
Priority to PT151812559T priority patent/PT2977061T/pt
Priority to EP14178214.4A priority patent/EP2810658B1/en
Priority to LTEP15181255.9T priority patent/LT2977061T/lt
Priority to EP17159693.5A priority patent/EP3202422A1/en
Priority to ES14178214.4T priority patent/ES2554468T3/es
Priority to DK15181255.9T priority patent/DK2977061T3/da
Priority to SI200632182T priority patent/SI2977061T1/sl
Priority to MX2008001129A priority patent/MX2008001129A/es
Priority to PL14178214T priority patent/PL2810658T3/pl
Priority to JP2008524069A priority patent/JP2009502930A/ja
Priority to PT141782144T priority patent/PT2810658E/pt
Priority to PL15181255T priority patent/PL2977061T3/pl
Priority to CA002615688A priority patent/CA2615688A1/en
Priority to EP06788435.3A priority patent/EP1917035B1/en
Priority to PCT/US2006/028851 priority patent/WO2007016093A2/en
Assigned to ALZA CORPORATION reassignment ALZA CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JUNNARKAR, GUNJAN, CARR, JOHN PATRICK, DESJARDIN, MICHAEL A.
Publication of US20070027105A1 publication Critical patent/US20070027105A1/en
Assigned to DURECT CORPORATION reassignment DURECT CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALZA CORPORATION
Priority to IL188991A priority patent/IL188991A0/en
Priority to US13/301,727 priority patent/US20120330005A1/en
Assigned to ALZA reassignment ALZA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JUNNARKAR, GUNJAN, CARR, JOHN PATRICK, DESJARDIN, MICHAEL A
Priority to HK15101703.9A priority patent/HK1201185A1/zh
Priority to CY20151101018T priority patent/CY1117052T1/el
Priority to HK16108760.3A priority patent/HK1221633A1/zh
Priority to US15/250,822 priority patent/US20160361420A1/en
Priority to CY20171100745T priority patent/CY1119562T1/el
Priority to US16/542,230 priority patent/US11083796B2/en
Priority to US17/364,519 priority patent/US20220023424A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms

Definitions

  • the present invention relates to methods for reducing peroxide levels in non-polymeric preparations and to compositions used in and prepared by such methods.
  • SAIB Sucrose acetate isobutyrate
  • SAIB is a hydrophobic liquid with limited water solubility. It is soluble in a large number of biocompatible solvents. SAIB has an unusual property—it undergoes a dramatic change in viscosity with small additions of heat or with the addition of solvents. It is a very viscous liquid, having a viscosity of approximately 3200 poise at 37° C. SAIB is produced by the controlled esterification of natural sugar (sucrose) with acetic and isobutyric anhydrides. SAIB metabolizes to sucrose, acetic acid and isobutyric acid.
  • SAIB is orally non-toxic and is currently used to stabilize emulsions in the food industry.
  • SAIB is commonly found in the beverage industry, where it is used as a weighting agent to help stabilize the final beverage formula.
  • SAIB has been reported to be useful as a gelling system-type drug excipient that allows for sustained or controlled release of drugs.
  • SAIB can be applied via injection or an aerosol spray.
  • SAIB is compatible with cellulose esters and other polymers that can affect the rate of delivery of the substance.
  • SAIB is the main ingredient for the SABER drug delivery system, which also consists of a pharmaceutically acceptable solvent.
  • Drug delivery systems including SAIB delivery systems, are still confronted by various issues of drug instability, as such systems are considered for longer and longer drug delivery durations.
  • Drug instability can occur via a number of factors, including denaturation, precipitation, oxidation, aggregation, and others.
  • a number of excipients used to facilitate delivery and release of drugs have peroxides or are susceptible to the formation of peroxides, which may lead to oxidation of active ingredient in the formulation.
  • the presence of peroxides is deleterious to a drug incorporated in an SAIB drug formulation as the drug is likely to undergo oxidative degradation.
  • the peroxide levels must be reduced.
  • An aspect of the present invention comprises methods of treating sucrose acetate isobutyrate (SAIB) formulations to be used as drug delivery vehicles comprising adding to the formulations an amount of bisulfite salt effective to substantially remove peroxides, the bisulfite salt comprising sodium metabisulfite, potassium metabisulfite, sodium bisulfite, or potassium bisulfite, or a mixture thereof.
  • SAIB sucrose acetate isobutyrate
  • drug delivery vehicles adapted to provide prolonged stability of a drug that is to be delivered in vivo comprising sucrose acetate isobutyrate having substantially reduced levels of peroxide, the drug delivery vehicle being treated with an amount of bisulfite salt effective to substantially reduce levels of peroxide in said drug delivery vehicle, the bisulfite salt comprising sodium metabisulfite, potassium metabisulfite, sodium bisulfite, or potassium bisulfite, or a combination thereof.
  • FIG. 1 illustrates a bar graph of the results of Study I—Stability of omega-interferon in untreated SAIB.
  • FIG. 2 illustrates a bar graph of the results of Study IIa—Stability of omega-interferon in alumina treated SAIB.
  • FIG. 3 illustrates a bar graph of the results of Study IIb—Stability of omega-interferon in alumina treated SAIB.
  • FIG. 4 illustrates a bar graph of the results of Study III—Stability of omega-interferon in untreated SAIB.
  • FIG. 5 illustrates a bar graph of the results of Study VIb—Stability of omega-interferon in untreated SAIB.
  • FIG. 6 illustrates a bar graph of the results of Study VIa—Stability of omega-interferon in sodium metabisulfite treated SAIB.
  • FIG. 7 illustrates a bar graph that provides comparisons of oxidation of omega-IFN in sodium metabisulfite treated and untreated SAIB.
  • FIG. 8 illustrates an osmotically pump-driven implantable device, Duros® being an example, that facilitates in vivo delivery of an active agent in an SAIB vehicle.
  • sucrose acetate isobutyrate formulations that are to be used as drug delivery vehicles comprising adding an amount of a bisulfite salt effective for substantially removing peroxide from the formulations, the bisulfite salt comprising sodium metabisulfite, potassium metabisulfite, sodium bisulfite, or potassium bisulfite, or a combination thereof.
  • the bisulfite salt is sodium metabisulfite.
  • a ratio ranging from about 1:1 to about 1:4 (weight:volume) SAIB:aqueous solution of bisulfite salt (“aqueous bisulfite salt”) can be used.
  • the bisulfite salt is a metabisulfite salt.
  • the bisulfite salt is preferably sodium metabisulfite.
  • the ratio of the aqueous bisulfite salt to SAIB is 1:1.
  • a volume of sodium metabisulfite solution can be made up to 1 liter, and an approximate proportion of 1:1 of SAIB:aqueous sodium metabisulfite was used.
  • the aqueous bisulfite salt in SAIB can be from about 0.1% weight to volume of water (w/v) to about 50% w/v; preferably, from about 0.5% w/v to about 30% w/v.
  • the aqueous bisulfite salt is preferably from about 1% w/v to about 15% w/v.
  • the aqueous bisulfite salt is about 5% w/v solution in water.
  • the method removes peroxide to a level that is at least less than 50% of the levels before the method, or starting levels, and, preferably, less than 20% of the starting levels. In some embodiments, peroxide is removed to less than 10% of the starting levels. While in some embodiments, the method removes peroxide to a level that is less than 5% of the starting levels. Furthermore, the method can remove peroxide so that the resulting SAIB formulation contains peroxide in amounts less than 20 ppm, and, preferably, less than 10 ppm. In some embodiments, the method removes peroxide to result in an SAIB formulation containing less than 5 ppm.
  • the resulting SAIB formulation from this method can serve as a drug delivery vehicle for use with a medical delivery device, including a drug eluting stent, a catheter, or other drug delivery implants.
  • the SAIB formulation can be loaded into an osmotically pump-driven implantable device of the type disclosed in U.S. Pat. No. 6,395,292, for example.
  • the osmotically pump-driven implantable device is a Duros® device (Alza Corporation, Mountain View, Calif.).
  • the SAIB formulation can serve as a drug depot for drug delivery.
  • the step of adding the bisulfite salt comprises mixing a solution of the bisulfite salt with the sucrose acetate isobutyrate formulation.
  • the SAIB formulation can be further comprised of a cosolvent, which can be selected from a number of solvents including pharmaceutically acceptable solvents, e.g., hexane, ethyl acetate, ethanol, benzyl benzoate, N-methyl pyrrolidone, and iso-propyl alcohol, among others.
  • the cosolvent is hexane or ethyl acetate.
  • the methods further comprise vacuum treating the formulation to remove the cosolvent.
  • some embodiments comprise the additional step of removing bisulfite salt from the formulation.
  • This removal step comprises washing the formulation with water to remove the bisulfite salt.
  • a further step of drying the formulation over magnesium sulfate can be utilized to remove the water.
  • calcium chloride anhydrous, calcium sulfate anhydrous, activated silica gel, phosphorous pentoxide, or drying under vacuum, or a combination thereof can be used to also remove the water.
  • glycerin can be used to wash the bisulfite-added formulation to remove the bisulfite salt. Afterwards, residual glycerin can be removed by washing with water and then drying to remove water.
  • the methods of substantially removing peroxide from a sucrose acetate isobutyrate formulation comprising the steps of adding the aqueous bisulfite salt, washing the formulation, and drying the formulation are repeated at least once. The steps can be repeated to further reduce the levels of peroxide in the SAIB formulation.
  • the present invention includes a drug delivery vehicle comprising SAIB that provides for prolonged stability of a drug that is to be delivered by maintaining substantially reduced levels of peroxide, the drug delivery vehicle being treated with sodium metabisulfite.
  • the prolonged stability comprises reduced oxidation, deamidation, or aggregation, e.g., dimerization, of the drug over extended periods of time in which drug is within environment of delivery vehicle.
  • the prolonged stability is reduced oxidation.
  • the extended periods of time can be periods from about one week to a few months, and up to about a year.
  • the prolonged stability is evidenced by significant improvements in oxidation, deamidation, or aggregation levels of the drug when the delivery vehicle has been treated with a bisulfite salt versus untreated delivery vehicle.
  • the prolonged stability is characterized as about 50% less oxidation, about 33% less deamidation, or about 75% less dimerization as compared to untreated delivery vehicles.
  • the drug can be selected from any known and desired biomolecular material that can act as therapeutics and other therapeutic active agents that are susceptible to oxidative degradation.
  • biomolecular material refers to peptides, polypeptides, proteins, nucleic acids, viruses, antibodies, small molecules susceptible to oxidation, and any other naturally derived, synthetically produced, or recombinantly produced active agent that includes nucleic or amino acid.
  • drugs can be selected from among the following: a steroid, NSAIDS, peptides, proteins such as growth factors or hormones, anti-tumor agents, antibiotics, analgesics, local anesthetics, antiviral agents, antipsychotics, anticoagulants, oligonucleotides for gene therapy, active small molecules, and others.
  • the term “removing” and all variations thereof, refer to decreasing by any measurable degree the level of peroxide present in a drug formulation.
  • the term “substantially removing” is used herein to describe a dramatic decrease in the level of peroxide present in a drug formulation, such as SAIB formulation. The dramatic decrease is at least 50% of original levels (levels before treatment) and in some instances is 10% of original levels. In preferred aspects of the present invention, the “substantial removal” describes a decrease to less than 5% of original levels.
  • drug delivery vehicle or “delivery vehicle” refers to a formulation that is biocompatible and used to carry a drug without reacting with the same drug. Also, the vehicle does not alter or minimally alters the activity of the drug. Furthermore, the vehicle allows for the transport of the drug in vivo and eventual delivery of the drug to a biological site for therapeutic effect.
  • Prolonged stability is used to refer to the stabilizing effect of the drug delivery vehicles of the present invention on the carried drug. Prolonged stability can be evidenced by significant improvements in oxidation, deamidation, or aggregation of the drug over extended periods of time.
  • Each of the experiments involved protein particles consisting of omega-interferon, which were suspended in SAIB at a particle loading of either 4% or 10% by weight.
  • the suspensions were prepared in a dry box under nitrogen at 45° C. The suspension was mixed for 15 minutes while maintaining the temperature. Suspension mixing was performed by hand. Aliquots from the prepared suspensions were transferred to clear crimp-top glass vials and sealed under nitrogen. Each aliquot contained at least six milligrams of protein to allow for stability testing in triplicate. These samples were stored in an oven at 40° C. Samples were withdrawn at regular intervals (as indicated in Table 1) and analyzed for omega-interferon content and purity was assessed using reverse phase HPLC and size exclusion chromatography.
  • Size exclusion chromatography was used to monitor the omega-interferon content and purity in the formulations. The percentages of monomer and dimer in the formulation were quantified using SEC. The stability of omega-interferon was judged by using a stability indicating chromatographic technique based on reverse phase HPLC (rp-HPLC). This technique was used to monitor the oxidation, deamidation and formation of an unknown species of omega-interferon in the formulations. The peroxide content of the vehicle was determined using EP 2002, 2.5.5 (Method A with auto titration). See Extra Pharmacopoeia, 2002 Ed. Content and purity assay of omega-interferon by size exclusion chromatography (SEC).
  • SEC Size exclusion chromatography
  • omega-interferon The stability of omega-interferon was monitored in two different lots of untreated SAIB (as received) and in treated SAIB (removal of peroxides), when treatment was applied.
  • Study IIa Treatment of SAIB (lot #TD1030507) with neutral alumina by heating and stability in this treated SAIB for 4 weeks
  • Study VIa Treatment of SAIB (lot #TD2032663) with 5% aqueous solution of sodium metabisulfite and stability in treated SAIB for 8 weeks
  • Study VIb Stability in untreated SAIB (lot #TD2032663) for 8 weeks TABLE 1 Details about stability studies of omega-interferon in SAIB SAIB Particle Time Study # (Lot #) Treatment loading points Tests I TD1030507 Untreated 4% 0, 4, 7, SEC, RP-HPLC 14 days IIa TD1030507 Treated with neutral 10% 0, 2, SEC, RP-HPLC alumina by heating 4 weeks IIb TD1030507 Treated with neutral 10% 0, 2, SEC, RP-HPLC alumina using ethanol 4 weeks III TD2032663 Untreated 10% 0, 1, SEC, RP-HPLC 2 weeks IV TD2032663 Treated with basic NA NA NA alumina by heating V TD2032663 Treated with 10% NA NA NA aqueous solution of methionine VIa TD2032663 Treated with hexane 10% 0, 1, 2, 4, SEC, RP-HPLC and 8 weeks sodium metabisulfite VIb TD2032663 Untreated 10% 0, 1, 2, 4, S
  • SAIB was heated to 75° C. Alumina (15% w/w) was added to the heated SAIB. The mixture was stirred for 40 minutes and filtered though a 5.0 ⁇ m filter at 75° C. The treated SAIB was then collected, sampled for peroxide testing, and used for preparation of suspension for stability testing.
  • SAIB was mixed with 15% absolute ethanol to reduce the viscosity.
  • Basic alumina (15% w/w) was added to the SAIB containing ethanol.
  • the resulting mixture was stirred for 1 hour and filtered though a 0.2 ⁇ m filter.
  • the filtered SAIB was placed overnight under vacuum at 60° C. to remove the ethanol. This treated SAIB was then collected, sampled for peroxide testing, and used for preparation of suspension for stability testing.
  • SAIB was heated to 90° C.
  • Basic alumina (15% w/w) was added to the heated SAIB.
  • Two different grades of alumina were used—Basic Super I and Basic Standard Activity I.
  • the resulting mixture was stirred for 40 minutes.
  • the mixture was then centrifuged at 4000 rpm while temperature was maintained at 75° C. After centrifugation, the supernatant was collected and sampled for peroxide analysis.
  • SAIB was vigorously agitated with 4 parts of 10% aqueous solution of methionine at 80° C. for 45 minutes using a magnetic stirrer. (Evaporated water was replenished as necessary) Afterwards, the methionine solution was decanted. SAIB was then washed with 4 parts of water by agitating for 15 minutes at 70°-80° C. This washing step was carried out three times. SAIB was placed overnight in vacuum oven at 70° C. to remove residual water, and, afterwards, was sampled for peroxide analysis.
  • SAIB was dissolved in two parts of hexane. The resulting solution was treated with a 5% aqueous solution of sodium metabisulfite by vigorous shaking. The aqueous layer was removed and the SAIB layer was washed with water. The SAIB layer was dried with MgSO 4 . Hexane was removed from SAIB by evaporation under vacuum at 50° C. The treated SAIB was sampled for peroxide analysis and used for preparation of suspension for stability testing.
  • treatment with an aqueous solution of sodium metabisulfite was effective in significantly reducing peroxide levels from 115.9 ppm to 2.6 ppm—almost 45 times, or 45 fold decrease.
  • treatment with neutral alumina either with heat or with ethanol, resulting in only a nominal change in peroxide levels—a 7% or 12% decrease, respectively.
  • treatment with basic alumina with heat or 10% aqueous methionine only resulted in nominal change in peroxide levels—a 6% or 18% decrease, respectively.
  • FIG. 8 illustrates an osmotically pump-driven implantable device for delivering an SAIB formulation acting as a drug delivery vehicle, active agent within.
  • an osmotically pump-driven implantable device 10 shown comprising an impermeable reservoir 12 .
  • the reservoir 12 is divided into two chambers by a piston 16 .
  • the first chamber 18 is adapted to contain an SAIB formulation 19 containing an active agent 20 and the second chamber 21 is adapted to contain a fluid-imbibing agent.
  • a back-diffusion regulating outlet 22 is inserted into the open end of the first chamber 18 and a semipermeable membrane 24 encloses the open end of the second chamber 21 .
  • the piston 16 is driven towards the open end of the first chamber 18 by the osmotic pressure generated by the fluid-imbibing agent in the second chamber 21 .
  • the pressure created by the piston 16 can force the contents of the first chamber 18 out the opening, i.e., the SAIB formulation 19 comprising active agents 20 .
  • the release rate of the active agent can be governed by the osmotic pumping rate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US11/492,153 2005-07-26 2006-07-24 Peroxide removal from drug delivery vehicle Abandoned US20070027105A1 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
US11/492,153 US20070027105A1 (en) 2005-07-26 2006-07-24 Peroxide removal from drug delivery vehicle
EA200800415A EA200800415A1 (ru) 2005-07-26 2006-07-25 Удаление пероксида из носителя для доставки лекарственного средства
PT141782144T PT2810658E (pt) 2005-07-26 2006-07-25 Eliminação de peróxido de veículo de entrega de fármacos
BRPI0614156-0A BRPI0614156A2 (pt) 2005-07-26 2006-07-25 veìculo de dispensação de droga, método para tratar uma formulação de isobutirato de acetato de sacarose, e, formulação de isobutirato de acetato de sacarose
DK14178214.4T DK2810658T3 (en) 2005-07-26 2006-07-25 REMOVAL OF PEROXIDE FROM A vehicle for the administration of drug
ES15181255.9T ES2632496T3 (es) 2005-07-26 2006-07-25 Eliminación de peróxido de un vehículo de administración de fármaco
SI200631978T SI2810658T1 (sl) 2005-07-26 2006-07-25 Odstranitev peroksida iz naprave za dajanje zdravil
AU2006275987A AU2006275987A1 (en) 2005-07-26 2006-07-25 Peroxide removal from drug delivery vehicle
HUE14178214A HUE027925T2 (en) 2005-07-26 2006-07-25 Removal of peroxide from drug carrier
JP2008524069A JP2009502930A (ja) 2005-07-26 2006-07-25 薬物送達ビヒクルからの過酸化物の除去
PT151812559T PT2977061T (pt) 2005-07-26 2006-07-25 Eliminação de peróxido de veículo de entrega de fármacos
EP14178214.4A EP2810658B1 (en) 2005-07-26 2006-07-25 Peroxide removal from drug delivery vehicle
EP15181255.9A EP2977061B1 (en) 2005-07-26 2006-07-25 Peroxide removal from drug delivery vehicle
EP17159693.5A EP3202422A1 (en) 2005-07-26 2006-07-25 Peroxide removal from drug delivery vehicle
ES14178214.4T ES2554468T3 (es) 2005-07-26 2006-07-25 Eliminación de peróxido de un vehículo de administración de fármaco
DK15181255.9T DK2977061T3 (da) 2005-07-26 2006-07-25 Fjernelse af peroxid fra vehikel til indgivelse af lægemiddel
SI200632182T SI2977061T1 (sl) 2005-07-26 2006-07-25 Odstranitev peroksida iz naprave za dajanje zdravil
MX2008001129A MX2008001129A (es) 2005-07-26 2006-07-25 Remocion de peroxido a partir de un vehiculo de suministro de farmaco.
PL14178214T PL2810658T3 (pl) 2005-07-26 2006-07-25 Usuwanie nadtlenków z podłoża do dostarczania leków
KR1020087004459A KR20080059149A (ko) 2005-07-26 2006-07-25 약물 전달 비히클로부터의 과산화물 제거
PL15181255T PL2977061T3 (pl) 2005-07-26 2006-07-25 Usuwanie nadtlenków z podłoża do dostarczania leków
LTEP15181255.9T LT2977061T (lt) 2005-07-26 2006-07-25 Peroksido pašalinimas iš vaisto įvedimo nešiklio
CA002615688A CA2615688A1 (en) 2005-07-26 2006-07-25 Peroxide removal from drug delivery vehicle
EP06788435.3A EP1917035B1 (en) 2005-07-26 2006-07-25 Peroxide removal from drug delivery vehicle
PCT/US2006/028851 WO2007016093A2 (en) 2005-07-26 2006-07-25 Peroxide removal from drug delivery vehicle
IL188991A IL188991A0 (en) 2005-07-26 2008-01-24 Peroxide removal from drug delivery vehicle
US13/301,727 US20120330005A1 (en) 2005-07-26 2011-11-21 Peroxide removal from drug delivery vehicle
HK15101703.9A HK1201185A1 (zh) 2005-07-26 2015-02-16 從藥物遞送載體中去除過氧化氫
CY20151101018T CY1117052T1 (el) 2005-07-26 2015-11-13 Αφαιρεση υπεροξειδιου απο φορεα χορηγησης φαρμακου
HK16108760.3A HK1221633A1 (zh) 2005-07-26 2016-07-21 給藥載體中去除的過氧化物
US15/250,822 US20160361420A1 (en) 2005-07-26 2016-08-29 Peroxide removal from drug delivery vehicle
CY20171100745T CY1119562T1 (el) 2005-07-26 2017-07-13 Αφαιρεση υπεροξειδιου απο φορεα χορηγησης φαρμακου
US16/542,230 US11083796B2 (en) 2005-07-26 2019-08-15 Peroxide removal from drug delivery vehicle
US17/364,519 US20220023424A1 (en) 2005-07-26 2021-06-30 Peroxide removal from drug delivery vehicle

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70254605P 2005-07-26 2005-07-26
US11/492,153 US20070027105A1 (en) 2005-07-26 2006-07-24 Peroxide removal from drug delivery vehicle

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/301,727 Continuation US20120330005A1 (en) 2005-07-26 2011-11-21 Peroxide removal from drug delivery vehicle

Publications (1)

Publication Number Publication Date
US20070027105A1 true US20070027105A1 (en) 2007-02-01

Family

ID=37695158

Family Applications (5)

Application Number Title Priority Date Filing Date
US11/492,153 Abandoned US20070027105A1 (en) 2005-07-26 2006-07-24 Peroxide removal from drug delivery vehicle
US13/301,727 Abandoned US20120330005A1 (en) 2005-07-26 2011-11-21 Peroxide removal from drug delivery vehicle
US15/250,822 Abandoned US20160361420A1 (en) 2005-07-26 2016-08-29 Peroxide removal from drug delivery vehicle
US16/542,230 Active US11083796B2 (en) 2005-07-26 2019-08-15 Peroxide removal from drug delivery vehicle
US17/364,519 Abandoned US20220023424A1 (en) 2005-07-26 2021-06-30 Peroxide removal from drug delivery vehicle

Family Applications After (4)

Application Number Title Priority Date Filing Date
US13/301,727 Abandoned US20120330005A1 (en) 2005-07-26 2011-11-21 Peroxide removal from drug delivery vehicle
US15/250,822 Abandoned US20160361420A1 (en) 2005-07-26 2016-08-29 Peroxide removal from drug delivery vehicle
US16/542,230 Active US11083796B2 (en) 2005-07-26 2019-08-15 Peroxide removal from drug delivery vehicle
US17/364,519 Abandoned US20220023424A1 (en) 2005-07-26 2021-06-30 Peroxide removal from drug delivery vehicle

Country Status (20)

Country Link
US (5) US20070027105A1 (ru)
EP (4) EP2977061B1 (ru)
JP (1) JP2009502930A (ru)
KR (1) KR20080059149A (ru)
AU (1) AU2006275987A1 (ru)
BR (1) BRPI0614156A2 (ru)
CA (1) CA2615688A1 (ru)
CY (2) CY1117052T1 (ru)
DK (2) DK2977061T3 (ru)
EA (1) EA200800415A1 (ru)
ES (2) ES2632496T3 (ru)
HK (2) HK1201185A1 (ru)
HU (1) HUE027925T2 (ru)
IL (1) IL188991A0 (ru)
LT (1) LT2977061T (ru)
MX (1) MX2008001129A (ru)
PL (2) PL2977061T3 (ru)
PT (2) PT2810658E (ru)
SI (2) SI2810658T1 (ru)
WO (1) WO2007016093A2 (ru)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050010196A1 (en) * 2003-03-31 2005-01-13 Fereira Pamela J. Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems
US20050101943A1 (en) * 2003-11-06 2005-05-12 Alza Corporation Modular imbibition rate reducer for use with implantable osmotic pump
US20050112188A1 (en) * 2003-11-17 2005-05-26 Eliaz Rom E. Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
US20060184158A1 (en) * 2002-06-17 2006-08-17 Fereira Pamela J Osmotic delivery system with early zero order push power engine
US20060193918A1 (en) * 2005-02-03 2006-08-31 Rohloff Catherine M Solvent/polymer solutions as suspension vehicles
US20060246138A1 (en) * 2005-03-15 2006-11-02 Rohloff Catherine M Polyoxaester suspending vehicles for use with implantable delivery systems
US20070191818A1 (en) * 2003-03-31 2007-08-16 Dionne Keith E Osmotic pump with means for dissipating internal pressure
US20080071253A1 (en) * 1997-07-25 2008-03-20 Alza Corporation Osmotic Delivery System Flow Modulator Apparatus and Method
US20080091176A1 (en) * 2006-08-09 2008-04-17 Alessi Thomas R Osmotic delivery systems and piston assemblies for use therein
US20080112994A1 (en) * 2004-05-25 2008-05-15 Intarcia Therapeutics, Inc. Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US20080226689A1 (en) * 1999-02-08 2008-09-18 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20080226625A1 (en) * 1999-02-08 2008-09-18 Intarcia Therapeutics, Inc. Stable non- aqueous single phase viscous vehicles and formulations utlizing such vehicles
US20080260840A1 (en) * 2005-02-03 2008-10-23 Alessi Thomas R Suspension formulations of insulinotropic peptides and uses thereof
US20080269726A1 (en) * 2003-10-31 2008-10-30 Intarcia Therapeutics, Inc. Osmotic pump with self-retaining, fast-start membrane plug
EP2067471A1 (en) 2007-12-06 2009-06-10 Durect Corporation Oral pharmaceutical dosage forms
US20090202608A1 (en) * 2008-02-13 2009-08-13 Alessi Thomas R Devices, formulations, and methods for delivery of multiple beneficial agents
US20100092566A1 (en) * 2008-10-15 2010-04-15 Alessi Thomas R Highly concentrated drug particles, formulations, suspensions and uses thereof
US20110076317A1 (en) * 2009-09-28 2011-03-31 Alessi Thomas R Rapid establishment and/or termination of substantial steady-state drug delivery
US8354124B2 (en) 2002-12-13 2013-01-15 Durect Corporation Oral drug delivery system
WO2014144984A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with thixotropy and enhanced dissolution reproducibility and stability
WO2014144975A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9616055B2 (en) 2008-11-03 2017-04-11 Durect Corporation Oral pharmaceutical dosage forms
WO2018009566A1 (en) 2016-07-06 2018-01-11 Durect Corporation Oral dosage form with drug composition, barrier layer and drug layer
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2018165462A1 (en) 2017-03-08 2018-09-13 Intarcia Therapeutics, Inc Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
USD835783S1 (en) 2016-06-02 2018-12-11 Intarcia Therapeutics, Inc. Implant placement guide
US10159714B2 (en) 2011-02-16 2018-12-25 Intarcia Therapeutics, Inc. Compositions, devices and methods of use thereof for the treatment of cancers
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US10501517B2 (en) 2016-05-16 2019-12-10 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
WO2020077129A1 (en) 2018-10-11 2020-04-16 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA124768C2 (uk) 2016-06-30 2021-11-17 Дьюрект Корпорейшн Депо-препарат
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
EA201990127A1 (ru) 2016-12-30 2020-08-18 Дьюрект Корпорейшн Депо-препарат
US11273105B2 (en) * 2017-06-16 2022-03-15 Sorse Technology Corporation Method for preparing solid forms of plant extract
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법

Citations (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3473949A (en) * 1966-05-09 1969-10-21 Gen Motors Corp Method of forming acrylic resin surface coatings
US3797492A (en) * 1972-12-27 1974-03-19 Alza Corp Device for dispensing product with directional guidance member
US3962162A (en) * 1974-02-19 1976-06-08 Minnesota Mining And Manufacturing Company Rigidly bonded green ceramics and processes
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4305927A (en) * 1979-02-05 1981-12-15 Alza Corporation Method for the management of intraocular pressure
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5219572A (en) * 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5279608A (en) * 1990-12-18 1994-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Osmotic pumps
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5336057A (en) * 1991-09-30 1994-08-09 Nippon Densan Corporation Micropump with liquid-absorptive polymer gel actuator
US5368588A (en) * 1993-02-26 1994-11-29 Bettinger; David S. Parenteral fluid medication reservoir pump
US5511355A (en) * 1991-11-15 1996-04-30 Dingler; Gerhard Construction element
US5557318A (en) * 1994-07-12 1996-09-17 Koninklijke Ptt Nederland N.V. Method and apparatus for permitting a viewer to scan through a plurality of video signals provided by a transmitter
US5713847A (en) * 1994-02-09 1998-02-03 The University Of Iowa Research Foundation Human drug delivery device for tinnitus
US5728396A (en) * 1996-02-02 1998-03-17 Alza Corporation Sustained delivery of leuprolide using an implantable system
US5836935A (en) * 1994-11-10 1998-11-17 Ashton; Paul Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US5874388A (en) * 1997-04-02 1999-02-23 Dow Corning Corporation Lubricant composition for disc brake caliper pin and a disc brake asembly containing the lubricant
US5976109A (en) * 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
US5997527A (en) * 1997-03-24 1999-12-07 Alza Corporation Self adjustable exit port
US5997902A (en) * 1993-06-23 1999-12-07 Alza Corporation Ruminal drug delivery device
US6113938A (en) * 1997-12-30 2000-09-05 Alza Corporation Beneficial agent delivery system with membrane plug and method for controlling delivery of beneficial agents
US6132420A (en) * 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6156331A (en) * 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6261584B1 (en) * 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6270787B1 (en) * 1997-12-29 2001-08-07 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
US6283949B1 (en) * 1999-12-27 2001-09-04 Advanced Cardiovascular Systems, Inc. Refillable implantable drug delivery pump
US6375978B1 (en) * 1997-12-22 2002-04-23 Alza Corporation Rate controlling membranes for controlled drug delivery devices
US6395292B2 (en) * 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6508808B1 (en) * 1999-12-21 2003-01-21 Alza Corporation Valve for osmotic devices
US20030044467A1 (en) * 1996-12-20 2003-03-06 Brodbeck Kevin J. Gel composition and methods
US20030059376A1 (en) * 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US20030180364A1 (en) * 2001-11-14 2003-09-25 Guohua Chen Catheter injectable depot compositions and uses thereof
US20030215515A1 (en) * 2002-04-11 2003-11-20 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
US6840931B2 (en) * 1997-07-25 2005-01-11 Alza Corporation Osmotic delivery system flow modulator apparatus and method
US20050008661A1 (en) * 2003-03-31 2005-01-13 Fereira Pamela J. Non-aqueous single phase vehicles and formulations utilizing such vehicles
US20050095284A1 (en) * 2003-10-31 2005-05-05 Alza Corporation Osmotic pump with self-retaining, fast-start membrane plug

Family Cites Families (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2931802A (en) 1958-04-30 1960-04-05 Eastman Kodak Co Mixed esters of glucose and sucrose
US3215137A (en) 1960-08-03 1965-11-02 Kendall & Co Immobilizing bandage and method of application
GB1088992A (en) 1963-09-19 1967-10-25 Squibb & Sons Inc Protective dressings
US3346381A (en) * 1964-07-30 1967-10-10 Rca Corp Electrostatic recording element
US3755466A (en) * 1968-11-04 1973-08-28 Marathon Oil Co Selective decomposition of hydroperoxides in the presence of polymeric peroxides and recovery of the polymeric peroxides
US4069251A (en) 1969-02-08 1978-01-17 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler Continuous process for the manufacture of methionine
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3743398A (en) 1971-03-22 1973-07-03 Eastman Kodak Co Motion picture projector
US3763018A (en) * 1971-04-01 1973-10-02 Basf Ag Prevention of fouling in hydrocarbon separation
NO139560C (no) 1972-04-29 1979-04-04 Takeda Chemical Industries Ltd Analogifremgangsmaate til fremstilling av terapeutisk virksomme nonapeptidamid-derivater
JPS5088069A (ru) 1973-11-01 1975-07-15
DE2438350C3 (de) 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE2438352A1 (de) 1974-08-09 1976-02-26 Hoechst Ag Peptidcyclopropylamide mit lh-rh/fshrh-wirkung
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
JPS55154991A (en) 1979-05-23 1980-12-02 Hisamitsu Pharmaceut Co Inc Beta-d-fructopyranoside derivative
NZ194405A (en) 1979-08-02 1982-05-25 Dut Pty Ltd Producing liquid hydrocarbon streams by hydrogenation of fossil-based feedstock
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4562024A (en) 1982-07-06 1985-12-31 Sterling Drug Inc. Process for preparing granulate containing poorly compressible medicinally active matter
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
DE3716302C2 (de) 1987-05-15 1996-02-01 Henkel Kgaa Verbesserte resorbierbare Knochenwachse und ihre Verwendung
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
JPS59210024A (ja) 1983-05-13 1984-11-28 Taiyo Kagaku Kk トコフエロ−ル乳化物
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4891225A (en) 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4630019A (en) 1984-09-28 1986-12-16 Westinghouse Electric Corp. Molded case circuit breaker with calibration adjusting means for a bimetal
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
JPS61260860A (ja) * 1985-05-15 1986-11-19 T Hasegawa Co Ltd 酸性飲料に配合するための乳化組成物
JPS62419A (ja) 1985-06-26 1987-01-06 Shiseido Co Ltd 脂溶性ビタミン含有水溶性剤
US4780320A (en) 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
JPH0657722B2 (ja) 1986-05-27 1994-08-03 三菱化成株式会社 水溶性ポリマ−組成物
ATE107857T1 (de) 1986-06-10 1994-07-15 Euro Celtique Sa Zusammensetzung mit kontrollierter freisetzung von dihydrocodein.
DE3620685A1 (de) 1986-06-20 1987-12-23 Henkel Kgaa Neue mittel zur abdeckung unverletzter und/oder verletzter bereiche menschlicher oder tierischer haut
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5091171B2 (en) 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5391381A (en) 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US4795641A (en) 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
JPH0296516A (ja) 1988-09-29 1990-04-09 Dainippon Pharmaceut Co Ltd 粒剤およびその製造方法
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4987893A (en) 1988-10-12 1991-01-29 Rochal Industries, Inc. Conformable bandage and coating material
US5324520A (en) 1988-12-19 1994-06-28 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
GB8926612D0 (en) 1989-11-24 1990-01-17 Erba Farmitalia Pharmaceutical compositions
WO1991016929A1 (en) 1990-05-10 1991-11-14 Novo Nordisk A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
IT1240643B (it) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
US5110685A (en) 1990-05-18 1992-05-05 Exxon Chemical Patents, Inc. Low friction, abrasion resistant polymer coating
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH05508266A (ja) 1991-04-03 1993-11-18 イーストマン・コダック・カンパニー ＧａＡｓをドライエッチングするための高耐久性マスク
US5221698A (en) 1991-06-27 1993-06-22 The Regents Of The University Of Michigan Bioactive composition
JP3313124B2 (ja) 1991-07-31 2002-08-12 森下仁丹株式会社 親水性物質を内容物とするシームレスカプセルおよびその製法
US5487898A (en) 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
DE69231536T2 (de) 1991-08-26 2001-06-13 Abbott Lab Verbindungen und methoden zur sublingualen oder buccalen verabreichung von therapeutischen agentien
YU87892A (sh) 1991-10-01 1995-12-04 Eli Lilly And Company Lilly Corporate Center Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu
IL103275A0 (en) 1991-10-01 1993-02-21 Lilly Co Eli Injectable extended release formulations and methods
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
EP0609345B1 (en) 1991-10-21 1999-09-22 Peptech Limited Biocompatible implant for the timing of ovulation in mares
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
DK0615438T3 (da) 1991-12-05 1996-11-11 Mallinckrodt Veterinary Inc En carbohydratglasmatrix til langvarig frigivelse af et terapeutisk middel
WO1993011754A1 (en) 1991-12-11 1993-06-24 The Procter & Gamble Company Cetylpyridinium chloride and domiphen bromide in organic solvent
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
US5456679A (en) 1992-02-18 1995-10-10 Alza Corporation Delivery devices with pulsatile effect
WO1993019739A1 (en) 1992-03-30 1993-10-14 Alza Corporation Viscous suspensions of controlled-release drug particles
DE69331387T2 (de) 1992-09-10 2002-08-22 Childrens Medical Center Biodegradierbare polymeren matrizen mit verzoegerter freisetzung von lokalanaesthetika
EP0678018B1 (en) 1993-01-06 2003-04-09 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5340572A (en) 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
AU679511B2 (en) 1993-03-17 1997-07-03 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
EP0689423B1 (en) 1993-03-17 1997-09-17 Minnesota Mining And Manufacturing Company Aerosol formulation containing a diol-diacid derived dispersing aid
DK44193D0 (da) 1993-04-20 1993-04-20 Euromed I S Saarforbinding og klaebemiddel til en saarforbinding eller lignende
US5370864A (en) 1993-06-29 1994-12-06 The Procter & Gamble Company Breath protection microcapsules
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
DE4322826A1 (de) 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
US5442033A (en) 1993-07-20 1995-08-15 Ethicon, Inc. Liquid copolymers of epsilon-caprolactone and lactide
JP3257750B2 (ja) 1993-07-20 2002-02-18 エチコン・インコーポレーテツド ε−カプロラクトンおよびラクチドの液状コポリマー
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5505922A (en) 1993-08-13 1996-04-09 University Of Maryland At Baltimore Anesthetic pharmaceutical combination
JPH0753356A (ja) 1993-08-16 1995-02-28 Morishita Jintan Kk 酸化され易い油性物質を内容物とするシームレスカプセルおよびその製造方法
JPH07112940A (ja) 1993-08-26 1995-05-02 Takeda Chem Ind Ltd 徐放性非経口投与製剤およびその製造方法
US5578137A (en) 1993-08-31 1996-11-26 E. I. Du Pont De Nemours And Company Azeotropic or azeotrope-like compositions including 1,1,1,2,3,4,4,5,5,5-decafluoropentane
AU5895994A (en) 1993-10-04 1995-05-01 Mark Chasin Controlled release microspheres
JPH07115901A (ja) 1993-10-28 1995-05-09 Fuji Bibaretsuji:Kk ドコサヘキサエン酸高含有乳化組成物及び飲料
JPH09507233A (ja) 1993-12-29 1997-07-22 マトリクス ファーマスーティカル，インコーポレイティド 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物
ES2171186T3 (es) 1994-04-08 2002-09-01 Atrix Lab Inc Composiciones liquidas de difusion.
US5633000A (en) 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
AU695479B2 (en) 1994-09-23 1998-08-13 Darwin Discovery Limited Racemisation and asymmetric transformation processes used in the manufacture of levobupivacaine and analogues thereof
US5599852A (en) 1994-10-18 1997-02-04 Ethicon, Inc. Injectable microdispersions for soft tissue repair and augmentation
ATE248148T1 (de) 1994-10-25 2003-09-15 Darwin Discovery Ltd Verfahren zur herstellung von levobupivacaine und analoge
US5994548A (en) 1994-10-25 1999-11-30 Darwin Discovery Ltd. Crystallisation of levibupivacaine and analogues thereof
GB9501071D0 (en) 1995-01-18 1995-03-08 Chiroscience Ltd Racemisation
US6384227B2 (en) 1995-01-18 2002-05-07 Darwin Discovery Ltd. Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents
DE19520237A1 (de) 1995-06-02 1996-12-05 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen, enthaltend Oligomere oder Polymere von alpha-Hydroxycarbonsäuren
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
WO1996039995A1 (en) 1995-06-07 1996-12-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5942241A (en) 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
AU733867B2 (en) 1996-06-24 2001-05-31 Euro-Celtique S.A. Methods for providing safe local anesthesia
DE69739165D1 (de) 1996-07-08 2009-01-29 Penwest Pharmaceuticals Co Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US5801012A (en) 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
US5747051A (en) 1996-09-27 1998-05-05 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing an amide of a hydroxy fatty acid and a retinoid
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6572880B2 (en) 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6203813B1 (en) 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
DE19714765A1 (de) 1997-04-10 1998-10-15 Merck Patent Gmbh Verwendung von niedermolekularen, oligomeren Estern von alpha-Hydroxysäuren und/oder aromatischen o-Hydroxysäuren in kosmetischen Formulierungen
US5919473A (en) 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6051558A (en) 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
DE69818675T2 (de) 1997-07-29 2004-07-29 Alcon Laboratories, Inc., Fort Worth Galaktomannanpolymere und borat enthaltende augenarzneimittel
BR9814883A (pt) 1997-11-19 2000-10-03 Darwin Discovery Ltd Formulação anestésica
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
MXPA00012767A (es) 1998-06-29 2002-08-09 Pharmaceuticals Applic Asociat Metodos y composiciones transdermicas para el alivio del dolor.
US6312717B1 (en) 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression
US6248112B1 (en) 1998-09-30 2001-06-19 C. R. Bard, Inc. Implant delivery system
WO2000033866A1 (en) 1998-12-04 2000-06-15 Provalis Uk Limited Pharmaceutical compositions containing insulin
DE19858891A1 (de) 1998-12-19 2000-06-21 Merck Patent Gmbh Verbesserte Knochensiegel
US6498153B1 (en) 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
KR100858856B1 (ko) 1999-02-08 2008-09-17 인타르시아 세라퓨틱스 인코포레이티드 안정한 비수성 단일상 점성 비히클 및 그 비히클을이용하는 제형물
US6541021B1 (en) 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6291013B1 (en) 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
AU5025300A (en) 1999-06-18 2001-01-09 Southern Biosystems, Inc. Compositions for controlled release of the hormone gnrh and its analogs
US6283948B1 (en) 1999-07-13 2001-09-04 Ethicon, Inc. Trocar obturator having grooved passageway
EP1220682B1 (en) 1999-10-04 2006-11-22 Novartis Vaccines and Diagnostics, Inc. Stabilized liquid polypeptide-containing pharmaceutical compositions
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
AU2979201A (en) 1999-12-13 2001-06-18 Pacmin Investments Limited Method of digesting titanium containing material and products thereof
AU2092701A (en) 1999-12-17 2001-06-25 Durect Corporation Devices and methods in intracerebrospinal delivery of morphine-6-glucuronide
AU2001900A (en) 1999-12-29 2001-07-16 Progen S.R.L. Biocompatible hydrogel and method of its production
DE10190041D2 (de) 2000-01-11 2002-12-05 Roland Bodmeier Implantate, Partikel
US6572890B2 (en) 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
DE60125986T3 (de) 2000-02-08 2011-07-28 Allergan, Inc., 92612, Calif. Pharmazeutische Zusammensetzungen mit Botulinum Toxin
BR0002246A (pt) 2000-04-06 2003-04-15 Cristalia Prod Quimicos Farm Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis
US20010042590A1 (en) * 2000-04-17 2001-11-22 Neuburger Carl D. Method and device for making a magnetically mountable substrate construction form a selected substrate
AU2001259111B2 (en) 2000-04-19 2005-12-08 Durect Corporation Sustained release formulations comprising growth hormone
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US6495534B2 (en) 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
WO2002010436A2 (en) 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
FR2814308B1 (fr) 2000-09-15 2003-03-14 France Telecom Procede de gestion de l'usage d'une ligne de telecommunication et systeme de mise en oeuvre
CA2423431A1 (en) 2000-10-06 2002-04-11 Durect Corporation Devices and methods for management of inflammation
HU230686B1 (en) 2000-10-30 2017-08-28 Euro Celtique Sa Controlled release hydrocodone compositions
EP1335704A2 (en) 2000-11-16 2003-08-20 Durect Corporation Implant dosage form and use thereof for the delivery of a cholesterol lowering agent
JP4248236B2 (ja) 2000-11-29 2009-04-02 デュレクト コーポレイション 薬物送達装置からの送達を制御するための装置および方法
JP2004521111A (ja) 2001-01-25 2004-07-15 ユーロ−セルティーク，エス．エイ． 局所麻酔薬および使用法
JP4724354B2 (ja) 2001-02-23 2011-07-13 ジェネンテック， インコーポレイテッド 注射用の崩壊性ポリマー
DE10109861A1 (de) * 2001-03-01 2002-09-05 Bayer Ag Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate
US7318931B2 (en) 2001-06-21 2008-01-15 Genentech, Inc. Sustained release formulation
US20040142902A1 (en) 2001-11-08 2004-07-22 Struijker- Boudier Harry A.J. Implant dosage form and use thereof for the delivery of a cholosterol lowering agent
EP1446100B1 (en) 2001-11-14 2011-05-04 Durect Corporation Injectable depot compositions and uses thereof
GB2386066A (en) 2002-02-28 2003-09-10 Norbrook Lab Ltd Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
FR2838349B1 (fr) 2002-04-15 2004-06-25 Laurence Paris Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
EP1509182A4 (en) 2002-05-31 2009-12-30 Titan Pharmaceuticals Inc IMPLANTABLE POLYMERS DEVICE FOR THE DELAYED RELEASE OF BUPRENORPHINE
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20040109893A1 (en) 2002-06-25 2004-06-10 Guohua Chen Sustained release dosage forms of anesthetics for pain management
JP4417039B2 (ja) 2002-06-28 2010-02-17 太陽化学株式会社 水中油滴型乳化組成物
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
WO2004011032A1 (ja) 2002-07-26 2004-02-05 Mikasa Seiyaku Co., Ltd. 外用剤
IL166418A0 (en) 2002-07-31 2006-01-15 Alza Corp Injectable depot compositions and uses thereof
TW575722B (en) 2002-09-02 2004-02-11 Hannstar Display Corp Planar light source device and liquid crystal display
MXPA05002561A (es) 2002-10-25 2005-05-05 Pfizer Prod Inc Nuevas formulaciones de liberacion prolongada inyectables.
MXPA05004299A (es) 2002-10-25 2005-08-03 Pfizer Prod Inc Formulacion de liberacion prolongada de agentes activos arilheterociclicos en forma de suspension.
BR0315304A (pt) 2002-11-06 2005-08-16 Alza Corp Formulações com depósito para liberação controlada
EP1575569B1 (en) 2002-12-13 2010-09-29 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
US20040224903A1 (en) * 2002-12-19 2004-11-11 Stephen Berry Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
DE10312346A1 (de) 2003-03-20 2004-09-30 Bayer Healthcare Ag Kontrolliertes Freisetzungssystem
US7641643B2 (en) * 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
DE10322469A1 (de) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
US20050106304A1 (en) 2003-11-14 2005-05-19 Cook Phillip M. Sucrose acetate isobutyrate formulation
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
WO2005048742A1 (en) 2003-11-14 2005-06-02 Eastman Chemical Company Sucrose acetate isobutyrate formulation
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20050118206A1 (en) 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US20040224019A1 (en) 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
US20050232876A1 (en) 2004-04-19 2005-10-20 Robin Lynn Minga Skin care compositions
US20080023261A1 (en) 2004-05-14 2008-01-31 Yanmar Co., Ltd. Noise Proof Structure of Cabin
US20050266087A1 (en) 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
SI2767292T1 (sl) 2004-09-17 2017-01-31 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
WO2006083950A2 (en) 2005-02-03 2006-08-10 Alza Corporation Method for reducing the level of peroxides in bopcompatible polymer preparations
EP1877077A2 (en) 2005-02-03 2008-01-16 Intarcia Therapeutics, Inc. An implantable interferon-containing device
JP4531582B2 (ja) 2005-02-10 2010-08-25 アルパイン株式会社 地図更新処理用データ作成方法、地図更新方法及び装置
JP4501076B2 (ja) 2006-01-06 2010-07-14 ソニー株式会社 携帯無線通信端末
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DK2117521T3 (da) 2006-11-03 2012-09-03 Durect Corp Transdermale indgivelsessystemer omfattende bupivacain
CA2686137C (en) 2007-05-18 2021-01-12 Durect Corporation Improved depot formulations
US8415401B2 (en) 2007-12-06 2013-04-09 Durect Corporation Oral pharmaceutical dosage forms
SE531980C2 (sv) 2008-01-17 2009-09-22 Avtech Sweden Ab Flygstyrningsförfarande samt datorprogram och datorprogramprodukt för att genomföra förfarandet
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
WO2014144984A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with thixotropy and enhanced dissolution reproducibility and stability
CN105120659A (zh) 2013-03-15 2015-12-02 度瑞公司 用于降低溶解可变性的具有流变改性剂的组合物

Patent Citations (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3473949A (en) * 1966-05-09 1969-10-21 Gen Motors Corp Method of forming acrylic resin surface coatings
US3797492A (en) * 1972-12-27 1974-03-19 Alza Corp Device for dispensing product with directional guidance member
US3962162A (en) * 1974-02-19 1976-06-08 Minnesota Mining And Manufacturing Company Rigidly bonded green ceramics and processes
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4305927A (en) * 1979-02-05 1981-12-15 Alza Corporation Method for the management of intraocular pressure
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5219572A (en) * 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5312389A (en) * 1990-10-29 1994-05-17 Felix Theeuwes Osmotically driven syringe with programmable agent delivery
US5279608A (en) * 1990-12-18 1994-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Osmotic pumps
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5336057A (en) * 1991-09-30 1994-08-09 Nippon Densan Corporation Micropump with liquid-absorptive polymer gel actuator
US5511355A (en) * 1991-11-15 1996-04-30 Dingler; Gerhard Construction element
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5368588A (en) * 1993-02-26 1994-11-29 Bettinger; David S. Parenteral fluid medication reservoir pump
US5997902A (en) * 1993-06-23 1999-12-07 Alza Corporation Ruminal drug delivery device
US5713847A (en) * 1994-02-09 1998-02-03 The University Of Iowa Research Foundation Human drug delivery device for tinnitus
US5557318A (en) * 1994-07-12 1996-09-17 Koninklijke Ptt Nederland N.V. Method and apparatus for permitting a viewer to scan through a plurality of video signals provided by a transmitter
US5836935A (en) * 1994-11-10 1998-11-17 Ashton; Paul Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US6156331A (en) * 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US5985305A (en) * 1996-02-02 1999-11-16 Alza Corporation Sustained delivery of an active agent using an implantable system
US6132420A (en) * 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6395292B2 (en) * 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6261584B1 (en) * 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US5728396A (en) * 1996-02-02 1998-03-17 Alza Corporation Sustained delivery of leuprolide using an implantable system
US5976109A (en) * 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
US20030044467A1 (en) * 1996-12-20 2003-03-06 Brodbeck Kevin J. Gel composition and methods
US5997527A (en) * 1997-03-24 1999-12-07 Alza Corporation Self adjustable exit port
US6217906B1 (en) * 1997-03-24 2001-04-17 Alza Corporation Self adjustable exit port
US5874388A (en) * 1997-04-02 1999-02-23 Dow Corning Corporation Lubricant composition for disc brake caliper pin and a disc brake asembly containing the lubricant
US6840931B2 (en) * 1997-07-25 2005-01-11 Alza Corporation Osmotic delivery system flow modulator apparatus and method
US6375978B1 (en) * 1997-12-22 2002-04-23 Alza Corporation Rate controlling membranes for controlled drug delivery devices
US6270787B1 (en) * 1997-12-29 2001-08-07 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
US6113938A (en) * 1997-12-30 2000-09-05 Alza Corporation Beneficial agent delivery system with membrane plug and method for controlling delivery of beneficial agents
US20030059376A1 (en) * 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US6508808B1 (en) * 1999-12-21 2003-01-21 Alza Corporation Valve for osmotic devices
US6283949B1 (en) * 1999-12-27 2001-09-04 Advanced Cardiovascular Systems, Inc. Refillable implantable drug delivery pump
US20030180364A1 (en) * 2001-11-14 2003-09-25 Guohua Chen Catheter injectable depot compositions and uses thereof
US20030215515A1 (en) * 2002-04-11 2003-11-20 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
US20050008661A1 (en) * 2003-03-31 2005-01-13 Fereira Pamela J. Non-aqueous single phase vehicles and formulations utilizing such vehicles
US20050276856A1 (en) * 2003-03-31 2005-12-15 Fereira Pamela J Non-aqueous single phase vehicles and formulations utilizing such vehicles
US20050095284A1 (en) * 2003-10-31 2005-05-05 Alza Corporation Osmotic pump with self-retaining, fast-start membrane plug

Cited By (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080071253A1 (en) * 1997-07-25 2008-03-20 Alza Corporation Osmotic Delivery System Flow Modulator Apparatus and Method
US8992961B2 (en) 1999-02-08 2015-03-31 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US8372424B2 (en) 1999-02-08 2013-02-12 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US8048438B2 (en) 1999-02-08 2011-11-01 Intarcia Therapeutics, Inc. Stable non- aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US8268341B2 (en) 1999-02-08 2012-09-18 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US8173150B2 (en) 1999-02-08 2012-05-08 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utlizing such vehicles
US20080226625A1 (en) * 1999-02-08 2008-09-18 Intarcia Therapeutics, Inc. Stable non- aqueous single phase viscous vehicles and formulations utlizing such vehicles
US20080226689A1 (en) * 1999-02-08 2008-09-18 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20060184158A1 (en) * 2002-06-17 2006-08-17 Fereira Pamela J Osmotic delivery system with early zero order push power engine
US8354124B2 (en) 2002-12-13 2013-01-15 Durect Corporation Oral drug delivery system
US9918982B2 (en) 2002-12-13 2018-03-20 Durect Corporation Oral drug delivery system
US9233160B2 (en) 2002-12-13 2016-01-12 Durect Corporation Oral drug delivery system
US9517271B2 (en) 2002-12-13 2016-12-13 Durect Corporation Oral drug delivery system
US8420120B2 (en) 2002-12-13 2013-04-16 Durect Corporation Oral drug delivery system
US8398967B2 (en) 2002-12-19 2013-03-19 Intarcia Therapeutics, Inc. Particle formulations for use in pharmaceutical compositions
US20110208168A1 (en) * 2002-12-19 2011-08-25 Intarcia Therapeutics, Inc. Particle formulations for use in pharmaceutical compositions
US20070191818A1 (en) * 2003-03-31 2007-08-16 Dionne Keith E Osmotic pump with means for dissipating internal pressure
US20050010196A1 (en) * 2003-03-31 2005-01-13 Fereira Pamela J. Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems
US20080269726A1 (en) * 2003-10-31 2008-10-30 Intarcia Therapeutics, Inc. Osmotic pump with self-retaining, fast-start membrane plug
US20050101943A1 (en) * 2003-11-06 2005-05-12 Alza Corporation Modular imbibition rate reducer for use with implantable osmotic pump
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050112188A1 (en) * 2003-11-17 2005-05-26 Eliaz Rom E. Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
US9724293B2 (en) 2003-11-17 2017-08-08 Intarcia Therapeutics, Inc. Methods of manufacturing viscous liquid pharmaceutical formulations
US8257691B2 (en) 2003-11-17 2012-09-04 Intarcia Therapeutics, Inc. Composition and dosage form comprising a particle formulation and suspending vehicle
US7964183B2 (en) 2003-11-17 2011-06-21 Intarcia Therapeutics, Inc. Composition and dosage form comprising a particle formulation and suspending vehicle
US20100112070A1 (en) * 2003-11-17 2010-05-06 Intarcia Therapeutics, Inc. Composition and dosage form comprising a particle formulation and suspending vehicle
US20110195097A1 (en) * 2003-11-17 2011-08-11 Intarcia Therapeutics, Inc. Composition and dosage form comprising a particle formulation and suspending vehicle
US20080112994A1 (en) * 2004-05-25 2008-05-15 Intarcia Therapeutics, Inc. Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US8940316B2 (en) 2005-02-03 2015-01-27 Intarcia Therapeutics, Inc. Osmotic delivery comprising an insulinotropic peptide and uses thereof
US8299025B2 (en) 2005-02-03 2012-10-30 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US8460694B2 (en) 2005-02-03 2013-06-11 Intarcia Therapeutics, Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US8206745B2 (en) 2005-02-03 2012-06-26 Intarcia Therapeutics, Inc. Solvent/polymer solutions as suspension vehicles
US8211467B2 (en) 2005-02-03 2012-07-03 Intarcia Therapeutics, Inc. Osmotic drug delivery devices containing suspension formulations comprising particles having active agents and nonaqueous single-phase vehicles
US8440226B2 (en) 2005-02-03 2013-05-14 Intarcia Therapeutics, Inc. Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US10363287B2 (en) 2005-02-03 2019-07-30 Intarcia Therapeutics, Inc. Method of manufacturing an osmotic delivery device
US8114437B2 (en) 2005-02-03 2012-02-14 Intarcia Therapeutics, Inc. Solvent/polymer solutions as suspension vehicles
US20080260840A1 (en) * 2005-02-03 2008-10-23 Alessi Thomas R Suspension formulations of insulinotropic peptides and uses thereof
US9095553B2 (en) 2005-02-03 2015-08-04 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US20060193918A1 (en) * 2005-02-03 2006-08-31 Rohloff Catherine M Solvent/polymer solutions as suspension vehicles
US9682127B2 (en) 2005-02-03 2017-06-20 Intarcia Therapeutics, Inc. Osmotic delivery device comprising an insulinotropic peptide and uses thereof
US7959938B2 (en) 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
US8114430B2 (en) 2005-03-15 2012-02-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
US20060246138A1 (en) * 2005-03-15 2006-11-02 Rohloff Catherine M Polyoxaester suspending vehicles for use with implantable delivery systems
US10527170B2 (en) 2006-08-09 2020-01-07 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
US8801700B2 (en) 2006-08-09 2014-08-12 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
US20100185184A1 (en) * 2006-08-09 2010-07-22 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
US7879028B2 (en) 2006-08-09 2011-02-01 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
US20080091176A1 (en) * 2006-08-09 2008-04-17 Alessi Thomas R Osmotic delivery systems and piston assemblies for use therein
US20110166554A1 (en) * 2006-08-09 2011-07-07 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
EP3326621A1 (en) 2007-12-06 2018-05-30 Durect Corporation Oral pharmaceutical dosage forms
EP2067471A1 (en) 2007-12-06 2009-06-10 Durect Corporation Oral pharmaceutical dosage forms
US10206883B2 (en) 2007-12-06 2019-02-19 Durect Corporation Oral pharamaceutical dosage forms
US9655861B2 (en) 2007-12-06 2017-05-23 Durect Corporation Oral pharmaceutical dosage forms
US9592204B2 (en) 2007-12-06 2017-03-14 Durect Corporation Oral pharmaceutical dosage forms
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20090202608A1 (en) * 2008-02-13 2009-08-13 Alessi Thomas R Devices, formulations, and methods for delivery of multiple beneficial agents
US8926595B2 (en) 2008-02-13 2015-01-06 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US10441528B2 (en) 2008-02-13 2019-10-15 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20100092566A1 (en) * 2008-10-15 2010-04-15 Alessi Thomas R Highly concentrated drug particles, formulations, suspensions and uses thereof
US9616055B2 (en) 2008-11-03 2017-04-11 Durect Corporation Oral pharmaceutical dosage forms
US10328068B2 (en) 2008-11-03 2019-06-25 Durect Corporation Oral pharmaceutical dosage forms
US9884056B2 (en) 2008-11-03 2018-02-06 Durect Corporation Oral pharmaceutical dosage forms
EP3323423A1 (en) 2009-09-28 2018-05-23 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US10231923B2 (en) 2009-09-28 2019-03-19 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US10869830B2 (en) 2009-09-28 2020-12-22 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US8298561B2 (en) 2009-09-28 2012-10-30 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20110076317A1 (en) * 2009-09-28 2011-03-31 Alessi Thomas R Rapid establishment and/or termination of substantial steady-state drug delivery
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US10159714B2 (en) 2011-02-16 2018-12-25 Intarcia Therapeutics, Inc. Compositions, devices and methods of use thereof for the treatment of cancers
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US9907851B2 (en) 2013-03-15 2018-03-06 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US9855333B2 (en) 2013-03-15 2018-01-02 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US10300142B2 (en) 2013-03-15 2019-05-28 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US9555113B2 (en) 2013-03-15 2017-01-31 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
WO2014144975A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
WO2014144984A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with thixotropy and enhanced dissolution reproducibility and stability
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10583080B2 (en) 2014-09-30 2020-03-10 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
US11214607B2 (en) 2016-05-16 2022-01-04 Intarcia Therapeutics Inc. Glucagon-receptor selective polypeptides and methods of use thereof
US10501517B2 (en) 2016-05-16 2019-12-10 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
US11840559B2 (en) 2016-05-16 2023-12-12 I2O Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
EP3733694A1 (en) 2016-05-16 2020-11-04 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD912249S1 (en) 2016-06-02 2021-03-02 Intarcia Therapeutics, Inc. Implant removal tool
USD835783S1 (en) 2016-06-02 2018-12-11 Intarcia Therapeutics, Inc. Implant placement guide
USD962433S1 (en) 2016-06-02 2022-08-30 Intarcia Therapeutics, Inc. Implant placement guide
WO2018009566A1 (en) 2016-07-06 2018-01-11 Durect Corporation Oral dosage form with drug composition, barrier layer and drug layer
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US11654183B2 (en) 2017-01-03 2023-05-23 Intarcia Therapeutics, Inc. Methods comprising continuous administration of exenatide and co-administration of a drug
WO2018165462A1 (en) 2017-03-08 2018-09-13 Intarcia Therapeutics, Inc Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
WO2020077129A1 (en) 2018-10-11 2020-04-16 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use

Also Published As

Publication number Publication date
US11083796B2 (en) 2021-08-10
US20220023424A1 (en) 2022-01-27
PL2977061T3 (pl) 2017-09-29
EP2977061B1 (en) 2017-04-26
JP2009502930A (ja) 2009-01-29
ES2632496T3 (es) 2017-09-13
ES2554468T3 (es) 2015-12-21
PT2810658E (pt) 2015-10-30
PT2977061T (pt) 2017-07-19
CY1119562T1 (el) 2018-03-07
US20190365900A1 (en) 2019-12-05
US20160361420A1 (en) 2016-12-15
EP2810658B1 (en) 2015-09-09
EP2977061A1 (en) 2016-01-27
IL188991A0 (en) 2008-08-07
WO2007016093A2 (en) 2007-02-08
HK1201185A1 (zh) 2015-08-28
SI2977061T1 (sl) 2017-08-31
DK2810658T3 (en) 2015-12-14
EA200800415A1 (ru) 2008-08-29
HUE027925T2 (en) 2016-11-28
MX2008001129A (es) 2008-03-13
HK1221633A1 (zh) 2017-06-09
LT2977061T (lt) 2017-09-11
SI2810658T1 (sl) 2015-12-31
CA2615688A1 (en) 2007-02-08
EP2810658A1 (en) 2014-12-10
KR20080059149A (ko) 2008-06-26
EP1917035A2 (en) 2008-05-07
PL2810658T3 (pl) 2016-04-29
CY1117052T1 (el) 2017-04-05
EP1917035B1 (en) 2014-11-05
EP3202422A1 (en) 2017-08-09
BRPI0614156A2 (pt) 2012-01-24
AU2006275987A1 (en) 2007-02-08
WO2007016093A3 (en) 2007-08-02
US20120330005A1 (en) 2012-12-27
DK2977061T3 (da) 2017-08-07

Similar Documents

Publication Publication Date Title
US11083796B2 (en) Peroxide removal from drug delivery vehicle
JP6837457B2 (ja) 生分解性薬物送達組成物
US5597897A (en) Pharmaceutical formulations of osteogenic proteins
US6174856B1 (en) Stabilized insulin compositions
WO1994008599A1 (en) Ion-pairing of drugs for improved efficacy and delivery
WO1994008599A9 (en) Ion-pairing of drugs for improved efficacy and delivery
US20140378370A1 (en) Low viscosity highly concentrated suspensions
WO1993011785A1 (en) Stabilized parathyroid hormone composition
JP7220664B2 (ja) 液体医薬組成物
EP4385517A2 (en) Degarelix drug product
JP2022535555A (ja) Ｇｌｐ１／２二重アゴニストの非経口医薬組成物
JP2004536129A (ja) セツキシマブおよびポリオキシエチレンソルビタン脂肪酸エステルを含む液体製剤
JP3608802B2 (ja) 安定なカルシトニン医薬組成物及びその製造法
NZ223533A (en) A dried protein product coated with an ionic surfactant whereby protein bioactivity and solubility is maintained and method of preparation
JP6965474B1 (ja) テリパラチド又はその塩を含有するプレフィルドシリンジまたはカートリッジ製剤の振盪による白濁を抑制する方法
US20160095904A1 (en) Stabilized liquid formulation
JP2008528699A (ja) Ｂｏｐ適合性ポリマー調製物中の過酸化物レベルを下げる方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALZA CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JUNNARKAR, GUNJAN;DESJARDIN, MICHAEL A.;CARR, JOHN PATRICK;REEL/FRAME:018180/0634;SIGNING DATES FROM 20060817 TO 20060824

AS Assignment

Owner name: DURECT CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALZA CORPORATION;REEL/FRAME:020036/0194

Effective date: 20071024

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: ALZA, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JUNNARKAR, GUNJAN;DESJARDIN, MICHAEL A;CARR, JOHN PATRICK;SIGNING DATES FROM 20060817 TO 20060824;REEL/FRAME:032124/0777